Rekombinanter CD19 (Inebilizumab Biosimilar) Antikörper
Research Grade
Reaktivität: Human
ELISA
Wirt: Mammalian Cells
Monoclonal
unconjugated
Recombinant Antibody
-
- Target Alle CD19 (Inebilizumab Biosimilar) Produkte
- CD19 (Inebilizumab Biosimilar)
- Antikörpertyp
- Recombinant Antibody
- Reaktivität
- Human
-
Wirt
-
Mammalian Cells
- Expressionssystem
- Mammalian cells
-
Klonalität
- Monoklonal
-
Konjugat
- Dieser CD19 (Inebilizumab Biosimilar) Antikörper ist unkonjugiert
-
Applikation
- ELISA
- Verwendungszweck
- Inebilizumab Biosimilar - Anti-CD19 mAb
- Produktmerkmale
- Antibody Type: IgG1-kappa
- Aufreinigung
- Recombinant antibody expressed in mammalien cells and purified.
- Güteklasse
- Research Grade
- Isotyp
- IgG1 kappa
-
-
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Buffer
- PBS pH 7.5
- Lagerung
- -80 °C
- Informationen zur Lagerung
- store at -80°C
-
- Target
- CD19 (Inebilizumab Biosimilar)
- Abstract
- CD19 (Inebilizumab Biosimilar) Produkte
- Substanzklasse
- Biosimilar
- Hintergrund
-
MEDI-551
Inebilizumab is a humanized afucosylated monoclonal IgG1 antibody that targets the broadly expressed B-cell surface antigen CD19. Inebilizumab is cytolytic, which may be usefull to treat neuromyelitis optica spectrum disorder (NMOSD)through B-cell depletion. - CAS-Nummer
- 1299440-37-1
-
Sie sind hier:
